<DOC>
	<DOCNO>NCT02160158</DOCNO>
	<brief_summary>The purpose study evaluate relative bioavailability 2 new bead-in-capsule formulation compare commercial extended-release formulation ( feed fast ) ass effect sprinkle capsule content applesauce pharmacokinetics 5 hydroxymethyl tolterodine ( 5-HMT ) .</brief_summary>
	<brief_title>Study Estimate Relative Bioavailability Compared Commercial Extended-release Tablet Formulation Effects Food Or Sprinkling Applesauce Fesoterodine Sustained-release Beads-in-capsule Formulations Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male and/or female subject age 18 55 year ; Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication History uncontrolled narrow angle glaucoma , myasthenia gravis , gastric retention , severe ulcerative colitis toxic megacolon Evidence history clinically significant urologic disease [ urinary retention , obstructive disturbance bladder emptying , micturition disturbance , nocturia pollacisuria ( eg , benign prostate hyperplasia , urethral stricture , recurrent urinary tract infection ) ; Use tobacco nicotinecontaining product excess equivalent 5 cigarettes/day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Fesoterodine</keyword>
	<keyword>SR3</keyword>
	<keyword>SR4</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>sprinkle</keyword>
	<keyword>applesauce</keyword>
</DOC>